MGAT4C
gene geneOn this page
Also known as HGNT-IV-H
Summary
MGAT4C (MGAT4 family member C, HGNC:30871) is a protein-coding gene on chromosome 12q21.31-q21.32, encoding Alpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase C (Q9UBM8). Glycosyltransferase that participates in the transfer of N-acetylglucosamine (GlcNAc) to the core mannose residues of N-linked glycans.
Predicted to enable acetylglucosaminyltransferase activity. Predicted to be involved in protein N-linked glycosylation. Predicted to be located in Golgi membrane.
Source: NCBI Gene 25834 — RefSeq curated summary.
At a glance
- GWAS associations: 11
- Clinical variants (ClinVar): 56 total
- MANE Select transcript:
NM_001351288
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:30871 |
| Approved symbol | MGAT4C |
| Name | MGAT4 family member C |
| Location | 12q21.31-q21.32 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | HGNT-IV-H |
| Ensembl gene | ENSG00000182050 |
| Ensembl biotype | protein_coding |
| OMIM | 607385 |
| Entrez | 25834 |
Gene structure
Transcript identifiers
Ensembl transcripts: 24 — 20 protein_coding, 4 protein_coding_CDS_not_defined
ENST00000547225, ENST00000548651, ENST00000550365, ENST00000551751, ENST00000551921, ENST00000552435, ENST00000552808, ENST00000602941, ENST00000611864, ENST00000620241, ENST00000621808, ENST00000899085, ENST00000899086, ENST00000899087, ENST00000899088, ENST00000899089, ENST00000929698, ENST00000929699, ENST00000929700, ENST00000929701, ENST00000929702, ENST00000929703, ENST00000941410, ENST00000941411
RefSeq mRNA: 10 — MANE Select: NM_001351288
NM_001351282, NM_001351283, NM_001351284, NM_001351285, NM_001351286, NM_001351287, NM_001351288, NM_001351289, NM_001351291, NM_013244
CCDS: CCDS9030
Canonical transcript exons
ENST00000611864 — 5 exons
| Exon | Start | End |
|---|---|---|
| ENSE00001325078 | 85983523 | 85983670 |
| ENSE00002329282 | 86049674 | 86049723 |
| ENSE00003660404 | 85989400 | 85989552 |
| ENSE00003932392 | 86256239 | 86256391 |
| ENSE00003933422 | 85955667 | 85980430 |
Expression profiles
Bgee: expression breadth ubiquitous, 117 present calls, max score 83.96.
FANTOM5 (CAGE): breadth broad, TPM avg 2.0149 / max 163.1292, expressed in 193 samples.
FANTOM5 promoters (13 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 132373 | 0.5413 | 122 |
| 132371 | 0.2647 | 104 |
| 132388 | 0.2208 | 60 |
| 132372 | 0.2125 | 88 |
| 132385 | 0.2059 | 52 |
| 132387 | 0.1858 | 56 |
| 132374 | 0.1734 | 78 |
| 132390 | 0.0660 | 39 |
| 132386 | 0.0584 | 27 |
| 132384 | 0.0276 | 9 |
Top tissues by expression
131 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| ventricular zone | UBERON:0003053 | 83.96 | gold quality |
| corpus callosum | UBERON:0002336 | 81.05 | gold quality |
| male germ line stem cell (sensu Vertebrata) in testis | CL:0000089 ∩ UBERON:0000473 | 79.90 | gold quality |
| thyroid gland | UBERON:0002046 | 77.01 | gold quality |
| left lobe of thyroid gland | UBERON:0001120 | 76.33 | gold quality |
| cortical plate | UBERON:0005343 | 75.99 | gold quality |
| testis | UBERON:0000473 | 75.88 | gold quality |
| right lobe of thyroid gland | UBERON:0001119 | 75.58 | gold quality |
| left testis | UBERON:0004533 | 75.57 | gold quality |
| right testis | UBERON:0004534 | 75.15 | gold quality |
| superior frontal gyrus | UBERON:0002661 | 74.22 | gold quality |
| islet of Langerhans | UBERON:0000006 | 73.49 | gold quality |
| nucleus accumbens | UBERON:0001882 | 73.21 | gold quality |
| ganglionic eminence | UBERON:0004023 | 73.13 | gold quality |
| caudate nucleus | UBERON:0001873 | 72.64 | gold quality |
| prefrontal cortex | UBERON:0000451 | 72.18 | gold quality |
| putamen | UBERON:0001874 | 71.43 | gold quality |
| frontal cortex | UBERON:0001870 | 70.40 | gold quality |
| anterior cingulate cortex | UBERON:0009835 | 70.11 | gold quality |
| cerebral cortex | UBERON:0000956 | 69.06 | gold quality |
| primary visual cortex | UBERON:0002436 | 68.87 | gold quality |
| amygdala | UBERON:0001876 | 68.65 | gold quality |
| temporal lobe | UBERON:0001871 | 68.52 | gold quality |
| Brodmann (1909) area 9 | UBERON:0013540 | 68.35 | gold quality |
| dorsolateral prefrontal cortex | UBERON:0009834 | 68.28 | gold quality |
| right frontal lobe | UBERON:0002810 | 67.58 | gold quality |
| hypothalamus | UBERON:0001898 | 67.50 | gold quality |
| brain | UBERON:0000955 | 67.12 | gold quality |
| pituitary gland | UBERON:0000007 | 66.84 | gold quality |
| heart left ventricle | UBERON:0002084 | 66.65 | gold quality |
Single-cell (SCXA)
Detected in 3 experiment(s), a significant marker in 3.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-HCAD-35 | yes | 64.53 |
| E-HCAD-25 | yes | 9.08 |
| E-ANND-3 | yes | 8.22 |
Regulation
Is transcription factor: no
Literature-anchored findings (GeneRIF, showing 1)
- Association of MGAT4C with major neurocognitive disorder in the Mexican population. (PMID:33581268)
Cross-species orthologs
5 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | mgat4c | ENSDARG00000041791 |
| mus_musculus | Mgat4c | ENSMUSG00000019888 |
| rattus_norvegicus | Mgat4c | ENSRNOG00000004149 |
| drosophila_melanogaster | Mgat4a | FBGN0036446 |
| drosophila_melanogaster | Mgat4b | FBGN0036447 |
Paralogs (3): MGAT4A (ENSG00000071073), MGAT4B (ENSG00000161013), MGAT4D (ENSG00000205301)
Protein
Protein identifiers
Alpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase C — Q9UBM8 (reviewed: Q9UBM8)
Alternative names: N-acetylglucosaminyltransferase IV homolog, N-glycosyl-oligosaccharide-glycoprotein N-acetylglucosaminyltransferase IVc, UDP-N-acetylglucosamine: alpha-1,3-D-mannoside beta-1,4-N-acetylglucosaminyltransferase IVc
All UniProt accessions (3): Q9UBM8, F8VTY5, F8VWY2
UniProt curated annotations — full annotation on UniProt →
Function. Glycosyltransferase that participates in the transfer of N-acetylglucosamine (GlcNAc) to the core mannose residues of N-linked glycans. Catalyzes the formation of the GlcNAcbeta1-4 branch on the GlcNAcbeta1-2Manalpha1-3 arm of the core structure of N-linked glycans. Essential for the production of tri- and tetra-antennary N-linked sugar chains. Does not catalyze the transfer of GlcNAc to the Manalpha1-6 arm to form GlcNAcBeta1-4Manalpha1-6 linkage (‘GnT-VI’ activity).
Subcellular location. Golgi apparatus membrane.
Tissue specificity. Expressed in heart, adrenal gland, testis, liver, brain and fetal brain. Not expressed in pancreas.
Pathway. Protein modification; protein glycosylation.
Similarity. Belongs to the glycosyltransferase 54 family.
Isoforms (2)
| UniProt ID | Names | Canonical? |
|---|---|---|
| Q9UBM8-1 | 1 | yes |
| Q9UBM8-2 | 2 |
RefSeq proteins (10): NP_001338211, NP_001338212, NP_001338213, NP_001338214, NP_001338215, NP_001338216, NP_001338217, NP_001338218, NP_001338220, NP_037376 (=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR006759 | Glyco_transf_54 | Family |
| IPR056576 | MGAT4_A/B/C_C | Domain |
| IPR057279 | MGAT4 | Domain |
Pfam: PF04666, PF23524
Catalyzed reactions (Rhea), 1 shown:
- N(4)-{beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->3)-[beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->6)]-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-beta-D-GlcNAc}-L-asparaginyl-[protein] + UDP-N-acetyl-alpha-D-glucosamine = N(4)-{beta-D-GlcNAc-(1->2)-[beta-D-GlcNAc-(1->4)]-alpha-D-Man-(1->3)-[beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->6)]-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-beta-D-GlcNAc}-L-asparaginyl-[protein] + UDP + H(+) (RHEA:16057)
UniProt features (8 total): topological domain 2, glycosylation site 2, chain 1, transmembrane region 1, splice variant 1, sequence variant 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q9UBM8-F1 | 87.04 | 0.69 |
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Glycosylation sites (2): 84, 215
Function
Pathways and Gene Ontology
Reactome pathways
14 pathways
| ID | Pathway |
|---|---|
| R-HSA-9694548 | Maturation of spike protein |
| R-HSA-975577 | N-Glycan antennae elongation |
| R-HSA-1643685 | Disease |
| R-HSA-392499 | Metabolism of proteins |
| R-HSA-446203 | Asparagine N-linked glycosylation |
| R-HSA-5663205 | Infectious disease |
| R-HSA-597592 | Post-translational protein modification |
| R-HSA-948021 | Transport to the Golgi and subsequent modification |
| R-HSA-9679506 | SARS-CoV Infections |
| R-HSA-9694516 | SARS-CoV-2 Infection |
| R-HSA-9694635 | Translation of Structural Proteins |
| R-HSA-975576 | N-glycan antennae elongation in the medial/trans-Golgi |
| R-HSA-9772573 | Late SARS-CoV-2 Infection Events |
| R-HSA-9824446 | Viral Infection Pathways |
MSigDB gene sets: 111 (showing top):
LFA1_Q6, GOBP_PROTEIN_N_LINKED_GLYCOSYLATION, GOBP_CARBOHYDRATE_DERIVATIVE_METABOLIC_PROCESS, EVI1_05, CDP_01, YY1_02, BRN2_01, chr12q21, GOBP_CARBOHYDRATE_DERIVATIVE_BIOSYNTHETIC_PROCESS, TGCTGAY_UNKNOWN, TGIF_01, OCT1_07, HNF1_C, GATA1_02, RGAGGAARY_PU1_Q6
GO Biological Process (3): protein N-linked glycosylation (GO:0006487), viral protein processing (GO:0019082), obsolete protein glycosylation (GO:0006486)
GO Molecular Function (5): acetylglucosaminyltransferase activity (GO:0008375), alpha-1,3-mannosylglycoprotein 4-beta-N-acetylglucosaminyltransferase activity (GO:0008454), metal ion binding (GO:0046872), transferase activity (GO:0016740), glycosyltransferase activity (GO:0016757)
GO Cellular Component (3): Golgi membrane (GO:0000139), Golgi apparatus (GO:0005794), membrane (GO:0016020)
Reactome top-level categories
Rollup of top-12 pathways:
| Category | Pathways |
|---|---|
| Translation of Structural Proteins | 1 |
| N-glycan antennae elongation in the medial/trans-Golgi | 1 |
| Post-translational protein modification | 1 |
| Disease | 1 |
| Metabolism of proteins | 1 |
| Asparagine N-linked glycosylation | 1 |
| Viral Infection Pathways | 1 |
| SARS-CoV Infections | 1 |
| Late SARS-CoV-2 Infection Events | 1 |
| Transport to the Golgi and subsequent modification | 1 |
| SARS-CoV-2 Infection | 1 |
| Infectious disease | 1 |
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| glycoprotein biosynthetic process | 1 |
| viral process | 1 |
| viral gene expression | 1 |
| UDP-glycosyltransferase activity | 1 |
| hexosyltransferase activity | 1 |
| acetylglucosaminyltransferase activity | 1 |
| catalytic activity, acting on a glycoprotein | 1 |
| cation binding | 1 |
| catalytic activity | 1 |
| transferase activity | 1 |
| Golgi apparatus | 1 |
| bounding membrane of organelle | 1 |
| cytoplasm | 1 |
| endomembrane system | 1 |
| intracellular membrane-bounded organelle | 1 |
| cellular anatomical structure | 1 |
Protein interactions and networks
STRING
770 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| MGAT4C | MGAT5 | Q09328 | 565 |
| MGAT4C | MGAT5B | Q3V5L5 | 518 |
| MGAT4C | TMEM263 | Q8WUH6 | 479 |
| MGAT4C | TCP11L2 | Q8N4U5 | 433 |
| MGAT4C | SUSD4 | Q5VX71 | 421 |
| MGAT4C | M0QYU9 | M0QYU9 | 417 |
| MGAT4C | KLHL17 | Q6TDP4 | 408 |
| MGAT4C | NUDT17 | P0C025 | 404 |
| MGAT4C | SMIM7 | Q9BQ49 | 399 |
| MGAT4C | PPP1R1C | Q8WVI7 | 396 |
| MGAT4C | ST6GAL2 | Q96JF0 | 394 |
| MGAT4C | CDK17 | Q00537 | 389 |
| MGAT4C | B4GALT2 | O60909 | 388 |
| MGAT4C | GXYLT2 | A0PJZ3 | 386 |
| MGAT4C | POLR3C | Q9BUI4 | 382 |
IntAct
3 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| MGAT4C | GXYLT2 | psi-mi:“MI:0914”(association) | 0.530 |
BioGRID (65): GAL (Affinity Capture-MS), METRN (Affinity Capture-MS), PCSK1N (Affinity Capture-MS), HTRA1 (Affinity Capture-MS), HAPLN3 (Affinity Capture-MS), ITGA2 (Affinity Capture-MS), DSE (Affinity Capture-MS), NMU (Affinity Capture-MS), GLT8D2 (Affinity Capture-MS), GALNT12 (Affinity Capture-MS), KIAA0319L (Affinity Capture-MS), TMEM132A (Affinity Capture-MS), GXYLT2 (Affinity Capture-MS), GYLTL1B (Affinity Capture-MS), B4GALT6 (Affinity Capture-MS)
ESM2 similar proteins: A0A0A1H7M6, A1YGR5, A1YGR6, E9KID2, E9KID3, G7LG31, O00469, O36022, O43909, O74745, P14769, P23336, P27810, P32629, P39107, P50127, P53697, P97259, Q00314, Q08834, Q09199, Q09328, Q1L8D2, Q3L7M0, Q3U4G3, Q494Q2, Q4R4A8, Q4WV44, Q5GF25, Q5RD93, Q5SRI9, Q5ZLK4, Q6DE40, Q6NXH2, Q811A3, Q8R4G6, Q8SQ20, Q8VXZ5, Q8W486, Q8W4E6
Diamond homologs: A4IID1, A6NG13, O77836, Q4R4A8, Q4R854, Q4V8F8, Q5F407, Q5M854, Q5REP8, Q5U3T0, Q6GMK0, Q6GQI7, Q6ITT3, Q812F8, Q812G0, Q9D306, Q9D4R2, Q9DGD1, Q9UBM8, Q9UM21, Q9UQ53, A6H684
SIGNOR signaling
0 interactions.
Disease & clinical
Clinical variants and AI predictions
ClinVar
56 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 48 |
| Likely benign | 3 |
| Benign | 2 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
3711 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 12:85983517:ACTT:A | donor_loss | 1.0000 |
| 12:85983519:TTACG:T | donor_loss | 1.0000 |
| 12:85983520:TACGC:T | donor_loss | 1.0000 |
| 12:85983521:A:AC | donor_gain | 1.0000 |
| 12:85983521:ACG:A | donor_gain | 1.0000 |
| 12:85983522:C:A | donor_loss | 1.0000 |
| 12:85983522:C:CG | donor_gain | 1.0000 |
| 12:85983522:CG:C | donor_gain | 1.0000 |
| 12:85983522:CGC:C | donor_gain | 1.0000 |
| 12:85983522:CGCT:C | donor_gain | 1.0000 |
| 12:85983522:CGCTT:C | donor_gain | 1.0000 |
| 12:85983669:TC:T | acceptor_gain | 1.0000 |
| 12:85983669:TCC:T | acceptor_loss | 1.0000 |
| 12:85983670:CC:C | acceptor_gain | 1.0000 |
| 12:85983671:C:A | acceptor_loss | 1.0000 |
| 12:85983671:C:CC | acceptor_gain | 1.0000 |
| 12:85983672:T:G | acceptor_loss | 1.0000 |
| 12:85983679:C:CT | acceptor_gain | 1.0000 |
| 12:85983680:A:T | acceptor_gain | 1.0000 |
| 12:85989458:C:CA | donor_gain | 1.0000 |
| 12:86049669:CTCAC:C | donor_loss | 1.0000 |
| 12:86049670:TCACC:T | donor_loss | 1.0000 |
| 12:86049672:A:C | donor_loss | 1.0000 |
| 12:86049673:C:CA | donor_loss | 1.0000 |
| 12:86334063:A:AC | donor_gain | 1.0000 |
| 12:86334064:C:CC | donor_gain | 1.0000 |
| 12:86380500:T:TA | donor_gain | 1.0000 |
| 12:86435155:A:AC | donor_gain | 1.0000 |
| 12:86435155:A:T | donor_loss | 1.0000 |
| 12:86435156:C:CC | donor_gain | 1.0000 |
AlphaMissense
0 scored. Top likely-pathogenic:
dbSNP variants (sampled 300 via entrez): RS1000005139 (12:85964027 T>C,G), RS1000007890 (12:86187944 C>G), RS1000010410 (12:86744878 A>G), RS1000025480 (12:86058068 G>A), RS1000042741 (12:86703218 T>C), RS1000045757 (12:86578569 T>G), RS1000048585 (12:85975265 T>G), RS1000048934 (12:86319111 G>A), RS1000053419 (12:86008440 T>C), RS1000055550 (12:86063299 A>C), RS1000062744 (12:86744663 A>G), RS1000065708 (12:86370569 T>C), RS1000070095 (12:86505373 C>T), RS1000070256 (12:86713389 G>A,C), RS1000070594 (12:86185127 C>A,T)
Disease associations
OMIM: gene MIM:607385 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
11 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST002930_2 | Cobalt levels | 9.000000e-07 |
| GCST003264_1607 | Post bronchodilator FEV1/FVC ratio | 1.000000e-06 |
| GCST003264_411 | Post bronchodilator FEV1/FVC ratio | 5.000000e-07 |
| GCST003264_446 | Post bronchodilator FEV1/FVC ratio | 7.000000e-07 |
| GCST003264_449 | Post bronchodilator FEV1/FVC ratio | 7.000000e-07 |
| GCST003264_798 | Post bronchodilator FEV1/FVC ratio | 4.000000e-07 |
| GCST003264_804 | Post bronchodilator FEV1/FVC ratio | 7.000000e-07 |
| GCST003264_846 | Post bronchodilator FEV1/FVC ratio | 1.000000e-06 |
| GCST007327_63 | Smoking status (ever vs never smokers) | 4.000000e-08 |
| GCST007394_1 | Mitochondrial DNA copy number | 9.000000e-07 |
| GCST011769_4 | Schizophrenia | 2.000000e-08 |
EFO canonical traits (3, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0004713 | FEV/FVC ratio |
| EFO:0004318 | smoking behavior |
| EFO:0006312 | mitochondrial DNA measurement |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
22 total (human), top 22 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| Benzo(a)pyrene | affects methylation, decreases expression, decreases methylation, increases expression | 3 |
| aristolochic acid I | decreases expression | 1 |
| bisphenol A | affects cotreatment, decreases methylation, increases methylation | 1 |
| S-(1,2-dichlorovinyl)cysteine | affects response to substance, increases expression, affects cotreatment | 1 |
| Am 580 | decreases expression | 1 |
| 2-palmitoylglycerol | increases expression | 1 |
| (+)-JQ1 compound | decreases expression | 1 |
| excavatolide B | decreases expression | 1 |
| Rosiglitazone | decreases expression | 1 |
| Decitabine | affects expression | 1 |
| Fulvestrant | affects cotreatment, decreases methylation | 1 |
| Cadmium | decreases expression, increases abundance | 1 |
| Cisplatin | affects expression | 1 |
| Lipopolysaccharides | affects response to substance, affects cotreatment, increases expression | 1 |
| Rotenone | decreases expression | 1 |
| Silicon Dioxide | increases expression | 1 |
| Tretinoin | increases expression | 1 |
| Triclosan | increases expression | 1 |
| 1-Methyl-4-phenylpyridinium | decreases expression | 1 |
| Aflatoxin B1 | increases methylation | 1 |
| Asbestos, Serpentine | increases methylation | 1 |
| Cadmium Chloride | decreases expression, increases abundance | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.